Farms.com Home   News

Pork market dynamics - challenges & opportunities ahead

By farms.com

The pork industry is navigating through a period of significant changes as highlighted in the latest Rabobank quarterly report. Production is anticipated to slow down due to reduced sow herds in key regions such as China, the US, and some European countries, impacting the pork supply throughout 2024.   

Diseases add to the sector's difficulty, while trade is expected to face a downturn in the first half of the year, especially affected by logistical issues in the Red Sea and Suez Canal. 

Not all news is grim.  The decline in feed prices, with corn and soybeans dropping 15% to 25% over the past year, brings a ray of hope. This reduction is a crucial factor in improving pig farmers' margins, offering some stability in uncertain times. 

Consumer demand for pork remains strong, undeterred by inflation. The report predicts a slight improvement in pork consumption globally, as pork retains its appeal against pricier alternatives like beef. This trend is supported by easing inflation and an economic upturn in certain areas. 

Regional differences in production are clear. For instance, Brazil is witnessing growth due to strong international demand, contrasting with Asia's struggle against African Swine Fever (ASF) and economic pressures.  

The industry outlook for 2024 is mixed, with challenges such as disease outbreaks and trade restrictions on one hand, and opportunities like improved farm management and genetic advancements on the other.  This balance of factors will continue to shape the global pork market in the coming year. 


Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.